{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:37:57Z","timestamp":1763707077838,"version":"3.44.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,15]]},"DOI":"10.7759\/cureus.92366","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T13:14:55Z","timestamp":1757942095000},"source":"Crossref","is-referenced-by-count":1,"title":["Zanubrutinib\u2011Induced Symmetrical Soft Tissue Forearm Swelling in a Patient With Waldenstr\u00f6m Macroglobulinemia"],"prefix":"10.7759","author":[{"given":"Victor M","family":"Samperio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aishwarya","family":"Ghonge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantin A","family":"Dasanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam CS","year":"2020","unstructured":"Tam CS, Opat S, D'Sa S, et al.. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood. 2020, 136:2038-50. 10.1182\/blood.2020006844","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1704","article-title":"The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma","volume":"27","author":"Opat S","year":"2021","unstructured":"Opat S, Tedeschi A, Linton K, et al.. The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed\/refractory marginal zone lymphoma. Clin Cancer Res. 2021, 27:6323-32. 10.1158\/1078-0432.CCR-21-1704","journal-title":"Clin Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers KA","year":"2021","unstructured":"Rogers KA, Thompson PA, Allan JN, et al.. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia. Haematologica. 2021, 106:2364-73. 10.3324\/haematol.2020.272500","journal-title":"Haematologica"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized Phase III trial","volume":"39","author":"Byrd JC","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, et al.. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized Phase III trial. J Clin Oncol. 2021, 39:3441-52. 10.1200\/JCO.21.01210","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218772327","article-title":"Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia","volume":"25","author":"Dasanu CA","year":"2019","unstructured":"Dasanu CA. Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia. J Oncol Pharm Pract. 2019, 25:1003-5. 10.1177\/1078155218772327","journal-title":"J Oncol Pharm Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.10.001","article-title":"Bruton's tyrosine kinase inhibitor associated localized extremity edema and erythema","volume":"54","author":"Meledathu S","year":"2024","unstructured":"Meledathu S, Chu P, Feldman T, Goy AH, Rosenstein RK. Bruton's tyrosine kinase inhibitor associated localized extremity edema and erythema. JAAD Case Rep. 2024, 54:93-7. 10.1016\/j.jdcr.2024.10.001","journal-title":"JAAD Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2356257","article-title":"Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"17","author":"Javidi-Sharifi N","year":"2024","unstructured":"Javidi-Sharifi N, Brown JR. Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. Expert Rev Hematol. 2024, 17:201-10. 10.1080\/17474086.2024.2356257","journal-title":"Expert Rev Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/402050-zanubrutinibinduced-symmetrical-soft-tissue-forearm-swelling-in-a-patient-with-waldenstrm-macroglobulinemia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T13:14:56Z","timestamp":1757942096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/402050-zanubrutinibinduced-symmetrical-soft-tissue-forearm-swelling-in-a-patient-with-waldenstrm-macroglobulinemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.92366","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,15]]}}}